Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Author(s):
Heijde, D. van der; Braun, J.; Rudwaleit, M.; Purcaru, O.; Kavanaugh, A.
Published
2012
Publication type
Article / Letter to editor
Date issued
2012-10-31
Language
English
Is part of
Arthritis and Rheumatism (2012), Vol. 64, no. 10, p. S592-S592
